Core Viewpoint - The company, Zhijiang Biologics (688317.SH), has received notification from the World Health Organization (WHO) that its monkeypox virus nucleic acid testing kit (fluorescent PCR method) has been included in the WHO Emergency Use Listing (EUL) as of September 17, 2025, indicating WHO's recognition and endorsement of the product [1] Group 1 - The inclusion in the WHO EUL provides a procurement basis for WHO member countries and potential buyers, which is expected to facilitate the promotion and sales of the company's monkeypox products in relevant overseas markets [1]

之江生物公告称，公司产品猴痘病毒核酸检测试剂盒（荧光PCR法）于近日收到世界卫生组织通知，于 2025年9月17日被列入为WHO应急使用清单（EUL）。该产品采购期限为1年。被列入EUL表明WHO对 公司产品的认可和肯定，可为WHO成员国和各意向采购方提供采购依据，对公司猴痘产品在相关海外 市场的推广和销售起到推动作用。但该产品也面临市场竞争风险、从EUL除名的风险以及对利润影响的 不确定性风险。 ...

之江生物首次公开发行募集资金总额为210,378.05万元，募集资金净额为194,232.16万元，较原计划多 58,643.05万元。公司2021年1月12日披露招股书显示，公司拟募集资金135,589.11万元，计划用于体外诊 断试剂生产线升级项目、分子诊断工程研发中心建设项目、营销与服务网络升级项目、产品研发项目、 补充流动资金。 之江生物首次公开发行的发行费用总额为16,145.89万元，其中，保荐及承销费用为14,495.05万元。 上市第六个交易日，之江生物盘中最高报93.80元，为上市以来股价最高点。 中国经济网北京9月17日讯之江生物(688317.SH)今日收报25.11元，跌幅2.90%，总市值48.25亿元。目前 该股处于破发状态。 之江生物于2021年1月18日在上交所科创板上市，发行数量为48,676,088股，发行价格为43.22元/股，保 荐机构(主承销商)为海通证券股份有限公司(现名"国泰海通证券股份有限公司")，保荐代表人为王莉、 陈邦羽。 ...

法律意见书 浙江天册律师事务所 关于 上海之江生物科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 编号：TCYJS2025H1473 号 致：上海之江生物科技股份有限公司 浙江天册律师事务所（以下简称"本所"）接受上海之江生物科技股份有限 公司（以下简称"之江生物"或"公司"）的委托，指派本所律师参加公司 2025 年第一次临时股东大会，并根据《中华人民共和国证券法》（以下简称"《证券 法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）和《上市公 司股东会规则》（以下简称"《股东会规则》"）等法律、法规和其他有关规范 性文件的要求出具本法律意见书。 法律意见书 浙江天册律师事务所 关于上海之江生物科技股份有限公司 2025 年第一次临时股东大会的 在本法律意见书中，本所律师仅对本次股东大会召集、召开程序、出席人员 的资格、召集人的资格、表决程序及表决结果的合法有效性发表意见，不对会议 所审议的议案内容和该等议案中所表述的事实或数据的真 ...

2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688317 证券简称：之江生物 公告编号：2025-051 上海之江生物科技股份有限公司 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 15 日 （二） 股东大会召开的地点：上海市闵行区陈行路 2388 号 8 幢 102 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 165 | | --- | --- | | 普通股股东人数 | 165 | | 2、出席会议的股东所持有的表决权数量 | 73,635,616 | | 普通股股东所持有表决权数量 | 73,635,616 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 41.4803 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 41.4803 | （ ...

上海之江生物科技股份有限公司 2025 年第一次临时股东大会会议资料 证券代码：688317 证券简称：之江生物 上海之江生物科技股份有限公司 2025 年第一次临时股东大会会议资料 2025 年 9 月 1 上海之江生物科技股份有限公司 2025 年第一次临时股东大会会议资料 上海之江生物科技股份有限公司 2025 年第一次临时股东大会会议资料目录 | 2025 | 年第一次临时股东大会会议须知 | 3 | | --- | --- | --- | | 2025 | 年第一次临时股东大会会议议程 | 5 | | 2025 | 年第一次临时股东大会会议议案 | 7 | | | 议案一：《关于取消监事会并修订<公司章程>的议案》 | 7 | | | 议案二：《关于修订、制定部分公司治理制度的议案》 | 8 | | | 议案三：《关于部分募投项目变更的议案》 | 9 | 2 上海之江生物科技股份有限公司 2025 年第一次临时股东大会会议资料 上海之江生物科技股份有限公司 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《 ...

Group 1 - The medical device sector experienced a decline of 1.78% on September 2, with Jimin Health leading the losses [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] - Notable gainers in the medical device sector included Wende Biological, which rose by 7.61% to a closing price of 25.58, and Jinhao Medical, which increased by 6.66% to 29.48 [1] Group 2 - Jimin Health saw a significant drop of 10.02%, closing at 11.40, with a trading volume of 1.0859 million shares and a transaction value of 1.331 billion [2] - Other notable decliners included Rejing Biological, which fell by 8.72% to 186.79, and Yikang Haosheng, which decreased by 7.71% to 34.24 [2] - The medical device sector experienced a net outflow of 1.23 billion from major funds, while retail investors contributed a net inflow of 1.011 billion [2]

Financial Performance - The total revenue for ZhiJiang Bio (688317) in the 2025 mid-year report was 59.68 million yuan, a decrease of 36.91% year-on-year [1] - The net profit attributable to the parent company was -9.85 million yuan, representing a decline of 137.88% year-on-year [1] - The gross profit margin was 63.56%, down 14.76% year-on-year, while the net profit margin was -16.51%, a decrease of 160.04% year-on-year [1] - The total of selling, administrative, and financial expenses reached 26.31 million yuan, accounting for 44.09% of total revenue, an increase of 18137.82% year-on-year [1] - Earnings per share were -0.05 yuan, a decline of 135.71% year-on-year [1] Cash Flow and Debt - The company reported cash and cash equivalents of 2.506 billion yuan, a decrease of 9.42% year-on-year [1] - The accounts receivable decreased by 52.29% year-on-year to 39.89 million yuan [1] - Interest-bearing liabilities increased significantly by 12370.61% year-on-year to 2.666 million yuan [1] Business Evaluation - The company's historical median ROIC since its listing is 12.38%, with the worst year being 2024, which recorded a ROIC of -6.43% [2] - The company has experienced two years of losses since its listing, indicating a fragile business model [2] Fund Holdings - The largest fund holding ZhiJiang Bio is Dachen Jingheng Mixed A, with a scale of 397 million yuan and a recent net value of 3.405, which has increased by 97.9% over the past year [4] Research and Development - The company is focusing on vertical integration, extending its product, industry, and value chains, particularly in the development of innovative antibody drugs for cancer and autoimmune diseases [4] - The company has successfully screened several antibody drug molecules, with one entering the invention patent acceptance stage [4]

Meeting Overview - The fifth meeting of the supervisory board of Shanghai Zhijiang Biological Technology Co., Ltd. was held on August 27, 2025, with all three supervisors present, confirming the legality and validity of the meeting [1] Financial Reporting - The supervisory board approved the 2025 semi-annual report, stating that it accurately reflects the company's financial status and operational results [1] Fund Management - The supervisory board confirmed that the company manages and uses raised funds in compliance with relevant regulations, ensuring no harm to the interests of the company and shareholders, especially minority shareholders [2] - The special report on the storage and use of raised funds for the first half of 2025 was deemed truthful, accurate, and complete [2] Project Adjustments - The supervisory board agreed to change certain fundraising projects, which aligns with industry conditions and the company's strategic development, enhancing the efficiency of fund usage without adversely affecting normal operations [2][3] Governance Changes - The supervisory board decided to abolish the supervisory board, transferring its powers to the audit committee of the board of directors, with corresponding amendments to the company's articles of association [3] - The supervisory board approved the temporary use of idle raised funds for cash management, not exceeding 60 million RMB, to improve fund efficiency and generate investment returns [3]

Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on September 15, 2025, at 14:00 in Shanghai [1][3] - Voting will be conducted through a combination of on-site and online methods, utilizing the Shanghai Stock Exchange's network voting system [1][3] Voting Procedures - Shareholders can vote via the trading system from 9:15 to 9:25, 9:30 to 11:30, and 13:00 to 15:00 on the day of the meeting [1] - Internet voting will be available from 9:15 to 15:00 on the same day [1][2] Agenda Items - The meeting will review several non-cumulative voting proposals, including amendments to the management system for senior management compensation and the fund management system to prevent misuse by controlling shareholders [2][10] - All proposals have been approved by the company's board and supervisory committee [2] Attendance Requirements - Shareholders must be registered with the China Securities Depository and Clearing Corporation by the close of trading on September 9, 2025, to attend the meeting [5] - Registration for attendance must be completed at least 30 minutes before the meeting starts [5][9] Additional Services - The company will provide a reminder service for shareholders to ensure participation, utilizing smart SMS notifications [4] - Shareholders are responsible for their own travel and accommodation expenses [6]